Highlights

  • Anteo S samples are under evaluation by separator manufacturers in South Korea, the US, Japan and elsewhere in Asia.
  • The first 18650 cylindrical cell with the Ultranode 95 high-silicon anode was assembled and tested.
  • AnteoBind NXT CLIA kits and ELISA plates were soft-launched at ADLM 2026, tripling the Life Sciences pipeline.
  • AnteoTech received a $1.9 million R&D Tax Incentive refund, with cash of $11.0 million at quarter end.

AnteoTech Ltd (ASX:ADO), a supplier of chemicals and advanced materials to the lithium-ion battery and life sciences diagnostics markets, has released its activities update and Appendix 4C for the quarter ended 30 September 2026. The company focused on converting customer evaluations into sales across both of its businesses.

Advanced Battery Technologies

Samples of Anteo S are under evaluation by separator manufacturers in several countries, with one customer receiving a 40-litre sample, the largest single delivery to date. Customer trials are expected to conclude by the end of 2026. Under a binding agreement with Xerabrid, seven potential customers have requested ceramic-coated separator samples, with shipments expected before year end.

The first 18650 cylindrical cell using the Ultranode 95 high-silicon anode was assembled and tested at the Battery Innovation Centre in Indiana. Ultranode 70 met its target of more than 500 cycles at 70% capacity retention in commercial-format cells with Wyon AG. AnteoTech also signed an agreement with Airspeeder to develop battery designs for an eVTOL team, and attended The Battery Show in North America, where 20 new customers requested samples.

Life Sciences Progress

A $134,138 AnteoBind shipment was delivered to the Serum Institute of India in July, with a further order expected before the end of 2026. The initial stage of a CLIA program with a large global life sciences company was completed on schedule, and the next stage is underway.

At the ADLM 2026 conference in Anaheim, AnteoTech soft-launched AnteoBind NXT CLIA kits and prototype ELISA plates, generating leads that tripled the Life Sciences pipeline. Independent third-party testing has been commissioned in the US and UK.

Corporate and Financial Update

AnteoTech received an R&D Tax Incentive refund of $1.9 million in September. Cash stood at $11.0 million at 30 September 2026, including a $5.5 million term deposit, and the company has no bank debt. MD and CEO Merrill Gray said the refund "has further strengthened our balance sheet."

CFO Scott Waddell has resigned, and Luke Oxenham will succeed him from 23 November 2026. Ms Gray said, "Our focus remains on supplying samples for evaluation, supporting customer testing and converting evaluations into sales." The AGM will be held on 10 November 2026.

Key Takeaways

  • AnteoTech's battery materials are being evaluated by customers across multiple markets.
  • Ultranode anode technology reached key performance milestones.
  • New Life Sciences product launches significantly expanded the sales pipeline.
  • The R&D refund lifted cash to $11.0 million, with no bank debt.